文献速递淋巴瘤

复发难治性结节性淋巴细胞为主型霍奇金淋巴瘤的北美结局分析

Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
PubMed 文献 · Br J Haematol · 2021-01-01

该研究回顾性分析了1979年至2019年间两家机构收治的69例复发或进展性结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者,排除首次复发时已有组织学转化者。中位随访14年,一线治疗后中位无进展生存期(PFS-1)为4年;二线治疗后5年PFS-2为68%(95%CI 54-79%),5年OS-2达94%(95%CI 85-99%)。结论认为复发后结局良好,需开展生物学研究以指导治疗降阶梯。

要点

  • 复发/难治性NLPHL患者二线治疗后5年OS达94%,预后良好。
  • 二线治疗包括化疗、生物治疗、自体移植和单纯放疗等多种模式。
  • 因复发后结局优异,应考虑治疗降阶梯并开展生物学导向研究。

核心结论

  • 复发或进展性NLPHL患者二线治疗后5年总生存率仍高达94%,提示复发后结局良好。

研究设计与样本

  • 回顾性分析两家机构1979年4月至2019年1月诊断的69例复发或进展性NLPHL患者,排除首次复发时组织学转化者。

主要发现

  • 一线治疗后中位无进展生存期(PFS-1)为4年。
  • 二线治疗后5年无进展生存期(PFS-2)为68%(95%CI 54-79%)。
  • 二线治疗后5年总生存期(OS-2)为94%(95%CI 85-99%)。

关键数值与推荐

  • 难治性疾病定义为对治疗无反应和/或治疗结束后3个月内复发。
  • 二线治疗中化疗占41%(28例),生物治疗(利妥昔单抗、来那度胺或维布妥昔单抗)占20%(14例),高剂量化疗联合自体干细胞移植占20%(14例),单纯放疗占15%(10例)。

临床怎么用

  • 对于复发/难治性NLPHL,二线治疗可选择化疗、生物治疗、自体移植或放疗,总体生存结局优异。

局限性

  • 回顾性研究,样本量有限(69例),来自两家机构,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity, with limited data on the outcome in the relapsed/refractory setting. We evaluated the outcome of all patients diagnosed between 04/1979 and 01/2019 with relapsed or progressive NLPHL after initial active therapy at two institutions, refractory disease being defined as lack of response to treatment and/or relapse within three months of treatment. NLPHL patients with histological evidence of transformation at time of first relapse or progression were excluded. In total, 69 patients with recurrent NLPHL were included in the study. After a median follow-up after initial diagnosis of 14 years (range, 0·5-46 years), median progression-free survival after front-line treatment (PFS-1) was four years. Second-line therapy included chemotherapy in 28 (41%) patients, biological therapy (rituximab, lenalidomide or brentuximab vedotin) in 14 (20%), high-dose chemotherapy followed by autologous stem cell transplant in 14 (20%) and radiation therapy (RT) alone in 10 (15%). The five-year PFS after second-line therapy (PFS-2) was 68% [95% confidence interval (CI), 54-79%] but the five-year overall survival (OS) after second-line therapy (OS-2) remained excellent, at 94% (95% CI, 85-99%). Due to excellent outcome in case of recurrence, studies aimed at characterizing its biology to guide therapy de-escalation are needed.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Strati P, Cheng PTM, Steiner RE, et al. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021. PMID: 33517581. doi:10.1111/bjh.17281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。